Compile Data Set for Download or QSAR
maximum 50k data
Found 1129 of ic50 data for polymerid = 50003665
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591075(CHEMBL5200118)
Affinity DataIC50:  2nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614973(US20230271939, Example 11)
Affinity DataIC50:  2.30nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614966(US20230271939, Example 4)
Affinity DataIC50:  2.90nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591046(CHEMBL5202342)
Affinity DataIC50:  3nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614965(US20230271939, Compound Example 3 | US20230271939,...)
Affinity DataIC50:  3.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614965(US20230271939, Compound Example 3 | US20230271939,...)
Affinity DataIC50:  3.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614995(US20230271939, Example 33)
Affinity DataIC50:  4.20nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50072072(CHEMBL3407849)
Affinity DataIC50:  5nMAssay Description:Inhibition of human C-terminal His-tagged GCN2 expressed in Escherichia coli using AviTag C-terminal, N-terminal His-tagged eIF2alpha (3 to 315) as s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591045(CHEMBL5209076)
Affinity DataIC50:  5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591054(CHEMBL5179922)
Affinity DataIC50:  5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591066(CHEMBL5190023)
Affinity DataIC50:  5nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM615005(US20230271939, Comp Ex 4 | WO2018030466, Example 5)
Affinity DataIC50:  5.80nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM615001(US20230271939, Comp Ex 1)
Affinity DataIC50:  5.90nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614968(US20230271939, Example 6)
Affinity DataIC50:  6.70nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614963(US20230271939, Compound Example 1 | US20230271939,...)
Affinity DataIC50:  7.20nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614963(US20230271939, Compound Example 1 | US20230271939,...)
Affinity DataIC50:  7.20nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614971(US20230271939, Example 9)
Affinity DataIC50:  7.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614967(US20230271939, Example 5)
Affinity DataIC50:  7.80nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614969(US20230271939, Example 7)
Affinity DataIC50:  7.90nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591070(CHEMBL5208600)
Affinity DataIC50:  8nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591079(CHEMBL5196751)
Affinity DataIC50:  8nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614964(US20230271939, Example 2)
Affinity DataIC50:  8.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50591075(CHEMBL5200118)
Affinity DataIC50:  9nMAssay Description:Inhibition of GCN2 in human SK-OV-3 cells assessed as reduction in phosphorylation of eIF2alpha by cellular assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM614970(US20230271939, Example 8)
Affinity DataIC50:  9.90nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647275(US20240025884, Example 486)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647276(US20240025884, Example 487)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647277(US20240025884, Example 488)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647278(US20240025884, Example 489)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647282(US20240025884, Example 493)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647283(US20240025884, Example 494)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647284(US20240025884, Example 495)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647285(US20240025884, Example 496)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647286(US20240025884, Example 497)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647287(US20240025884, Example 498)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647288(US20240025884, Example 499)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647289(US20240025884, Example 500)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647290(US20240025884, Example 501)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647291(US20240025884, Example 502)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647292(US20240025884, Example 503)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647293(US20240025884, Example 504)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647294(US20240025884, Example 505)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647295(US20240025884, Example 506)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647185(US20240025884, Example 396)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647186(US20240025884, Example 397)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647188(US20240025884, Example 399)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647189(US20240025884, Example 400)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647190(US20240025884, Example 401)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647193(US20240025884, Example 404)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647197(US20240025884, Example 408)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargeteIF-2-alpha kinase GCN2(Homo sapiens (Human))
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM647200(US20240025884, Example 411)
Affinity DataIC50: <10nMAssay Description:384-well (Greiner #784075) (or 1536-well [Greiner #782075]) plates containing 60 nl (or 20 nl for 1536-well) of compound in 100% DMSO (10 concentrati...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
Displayed 1 to 50 (of 1129 total ) | Next | Last >>
Jump to: